Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Immunovant Says Results From Initial Cohort Of Patients In An Ongoing 24-week Phase 2 Clinical Trial Of Batoclimab In Patients With Graves' Disease Meaningfully Exceeded 50% Response Rates

Author: Benzinga Newsdesk | December 20, 2023 05:32pm

Batoclimab was generally well tolerated with no new safety signals observed in the initial data set.

Posted In: IMVT ROIV